BACKGROUND AND OBJECTIVES: The impact of dopaminergic medication on language in Parkinson's disease (PD) remains poorly understood. This observational, naturalistic study aimed to investigate the effects of long-term dopaminergic therapy on language performance in patients with de-novo PD based on a high-level linguistic analysis of natural spontaneous discourse. METHODS: A fairy-tale narration was recorded at baseline and a 12-month follow-up. The speech samples were automatically analyzed using six representative lexical and syntactic features based on automatic speech recognition and natural language processing. RESULTS: We enrolled 109 de-novo PD patients compared to 68 healthy controls. All subjects completed the 12-month follow-up; 92 PD patients were on stable dopaminergic medication (PD-treated), while 17 PD patients remained without medication (PD-untreated). At baseline, the PD-treated group exhibited abnormalities in syntactic domains, particularly in sentence length (p = 0.018) and sentence development (p = 0.042) compared to healthy controls. After 12 months of dopaminergic therapy, PD-treated showed improvements in the syntactic domain, including sentence length (p = 0.012) and sentence development (p = 0.030). Of all PD-treated patients, 37 were on monotherapy with dopamine agonists and manifested improvement in sentence length (p = 0.048), while 32 were on monotherapy with levodopa and had no language amelioration. No changes in language parameters over time were seen in both the PD-untreated group and healthy controls. DISCUSSION: Initiation of dopaminergic therapy improved high-language syntactic deficits in de-novo PD, confirming the role of dopamine in cognitive-linguistic processing. Automated linguistic analysis of spontaneous speech via natural language processing can assist in improving the prediction and management of language deficits in PD.

ARTORG Center for Biomedical Engineering Research University of Bern Bern Switzerland

Department of Circuit Theory Faculty of Electrical Engineering Czech Technical University Prague Technická 2 Praha 6 160 00 Prague Czech Republic

Department of Neurology and Centre of Clinical Neuroscience 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Zobrazit více v PubMed

Poewe W, Seppi K, Tanner CM et al (2017) Parkinson disease. Nat Rev Dis Primers 3:17013. 10.1038/nrdp.2017.13 PubMed

Aarsland D, Kurz MW (2010) The epidemiology of dementia associated with Parkinson’s disease. Brain Pathol 20(3):633–639. 10.1111/j.1750-3639.2009.00369.x PubMed PMC

Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60(3):387–392. 10.1001/archneur.60.3.387 PubMed

Boschi V, Catricalà E, Consonni M, Chesi C, Moro A, Cappa SF (2017) Connected speech in neurodegenerative language disorders: a review. Front Psychol 8:269. 10.3389/fpsyg.2017.00269 PubMed PMC

Murray LL (2000) Spoken language production in Huntington’s and Parkinson’s diseases. J Speech Lang Hear Res 43(6):1350–1366. 10.1044/jslhr.4306.1350 PubMed

Troche MS, Altmann LJP (2012) Sentence production in Parkinson disease: Effects of conceptual and task complexity. Appl Psycholinguist 33(2):225–251. 10.1017/S0142716411000336

Illes J, Metter EJ, Hanson WR, Iritani S (1988) Language production in Parkinson’s disease: acoustic and linguistic considerations. Brain Lang 33(1):146–160. 10.1016/0093-934x(88)90059-4 PubMed

Meder D, Herz DM, Rowe JB, Lehéricy S, Siebner HR (2019) The role of dopamine in the brain—lessons learned from Parkinson’s disease. Neuroimage 190:79–93. 10.1016/j.neuroimage.2018.11.021 PubMed

Sanchez J, Spencer KA (2013) Preliminary evidence of discourse improvement with dopaminergic medication. Adv Parkinson’s Dis 2(2):37–42. 10.4236/apd.2013.22007

Herrera E, Cuetos F, Ribacoba R (2012) Verbal fluency in Parkinson’s disease patients on/off dopamine medication. Neuropsychologia 50(14):3636–3640. 10.1016/j.neuropsychologia.2012.09.016 PubMed

Gotham AM, Brown RG, Marsden CD (1988) ‘Frontal’ cognitive function in patients with Parkinson’s disease ‘on’ and ‘off’ levodopa. Brain 111(2):299–321. 10.1093/brain/111.2.299 PubMed

Gul A, Yousaf J (2019) Effect of levodopa on frontal-subcortical and posterior cortical functioning in patients with Parkinson’s disease. Singapore Med J 60(8):414–417. 10.11622/smedj.2018116 PubMed PMC

Murakami H, Momma Y, Nohara T et al (2016) Improvement in language function correlates with gait improvement in drug-naïve Parkinson’s disease patients taking dopaminergic medication. J Parkinsons Dis 6(1):209–217. 10.3233/JPD-150702 PubMed

Dusek P, Bezdicek O, Brozová H et al (2020) Clinical characteristics of newly diagnosed Parkinson’s disease patients included in the longitudinal BIO-PD study. Cesk Slov Neurol N 83(116):633–639. 10.48095/cccsnn2020633

Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601. 10.1002/mds.26424 PubMed

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653. 10.1002/mds.23429 PubMed

Goetz CG, Fahn S, Martinez-Martin P et al (2007) Movement Disorder Society-sponsored revision of the Unified Parkinson’s disease rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 22(1):41–47. 10.1002/mds.21198 PubMed

Kopecek M, Stepankova H, Lukavsky J, Ripova D, Nikolai T, Bezdicek O (2017) Montreal cognitive assessment (MoCA): normative data for old and very old Czech adults. Appl Neuropsychol Adult 24(1):23–29. 10.1080/23279095.2015.1065261 PubMed

Strunk K, Lane F (2017) The beck depression inventory, second edition (BDI-II): a cross-sample structural analysis. Meas Eval Counsel Dev 50:3–17. 10.1080/07481756.2017.1318636

Ciharova M, Cígler H, Dostálová V, Šivicová G, Bezdicek O (2020) Beck depression inventory, second edition, Czech version: demographic correlates, factor structure and comparison with foreign data. Int J Psychiatry Clin Pract 24(4):371–379. 10.1080/13651501.2020.1775854 PubMed

Spielberger C, Gorsuch R, Lushene R, Vagg P, Jacobs G (1983) Manual for the state-trait anxiety inventory (form Y1–Y2). Vol IV

Šubert M, Šimek M, Novotný M, et al. Linguistic Abnormalities in Isolated Rapid Eye Movement Sleep Behavior Disorder. Movement Disorders. Published online July 7, 2022. 10.1002/mds.29140 PubMed

Subert M, Novotný M, Tykalová T et al (2023) Spoken language alterations can predict phenoconversion in isolated REM sleep behavior disorder: a multicentric study. Ann Neurol. 10.1002/ana.26835 PubMed

Radford A, Kim JW, Xu T, Brockman G, McLeavey C, Sutskever I (2022) Robust speech recognition via large-scale weak supervision. In: ICML’23: proceedings of the 40th international conference on machine learning

OpenAI (2023) Robust speech recognition via large-scale weak supervision. https://github.com/openai/whisper. Accessed September 2, 2024

Ardila R, Branson M, Davis K et al (2020) common voice: a massively-multilingual speech corpus. arXiv. 10.48550/arXiv.1912.06670

Conneau A, Ma M, Khanuja S et al (2022) FLEURS: few-shot learning evaluation of universal representations of speech. arXiv. 10.48550/arXiv.2205.12446

Qi P, Zhang Y, Zhang Y, Bolton J, Manning CD (2020) Stanza: a python natural language processing toolkit for many human languages. In: Proceedings of the 58th annual meeting of the association for computational linguistics: system demonstrations. https://nlp.stanford.edu/pubs/qi2020stanza.pdf

Covington MA, McFall JD (2010) Cutting the gordian knot: the moving-average type-token ratio (MATTR). J Quant Linguist 17(2):94–100. 10.1080/09296171003643098

Beltrami D, Gagliardi G, Rossini Favretti R, Ghidoni E, Tamburini F, Calzà L (2018) Speech analysis by natural language processing techniques: a possible tool for very early detection of cognitive decline? Front Aging Neurosci. 10.3389/fnagi.2018.00369 PubMed PMC

de Lira JO, Ortiz KZ, Campanha AC, Bertolucci PHF, Minett TSC (2011) Microlinguistic aspects of the oral narrative in patients with Alzheimer’s disease. Int Psychogeriatr 23(3):404–412. 10.1017/S1041610210001092 PubMed

Ash S, McMillan C, Gross RG et al (2011) The organization of narrative discourse in Lewy body spectrum disorder. Brain Lang 119(1):30–41. 10.1016/j.bandl.2011.05.006 PubMed PMC

Camerino I, Ferreira J, Vonk JM et al (2024) Systematic review and meta-analyses of word production abilities in dysfunction of the basal ganglia: stroke, small vessel disease, Parkinson’s disease, and Huntington’s disease. Neuropsychol Rev 34(1):1–26. 10.1007/s11065-022-09570-3 PubMed

Galtier I, Nieto A, Mata M, Lorenzo JN, Barroso J (2023) Specific pattern of linguistic impairment in Parkinson’s disease patients with subjective cognitive decline and mild cognitive impairment predicts dementia. J Int Neuropsychol Soc 29(7):632–640. 10.1017/S1355617722000571 PubMed

Lowit A, Thies T, Steffen J et al (2022) Task-based profiles of language impairment and their relationship to cognitive dysfunction in Parkinson’s disease. PLoS ONE 17(10):e0276218. 10.1371/journal.pone.0276218 PubMed PMC

Baiano C, Barone P, Trojano L, Santangelo G (2020) Prevalence and clinical aspects of mild cognitive impairment in Parkinson’s disease: a meta-analysis. Mov Disord 35(1):45–54. 10.1002/mds.27902 PubMed

Costa A, Peppe A, Dell’Agnello G, Caltagirone C, Carlesimo GA (2009) Dopamine and cognitive functioning in de novo subjects with Parkinson’s disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 47(5):1374–1381. 10.1016/j.neuropsychologia.2009.01.039 PubMed

Kulisevsky J, García-Sánchez C, Berthier ML et al (2000) Chronic effects of dopaminergic replacement on cognitive function in Parkinson’s disease: a two-year follow-up study of previously untreated patients. Mov Disord 15(4):613–626. 10.1002/1531-8257(200007)15:4%3c613::aid-mds1005%3e3.0.co;2-f PubMed

Rektorová I (2010) Effects of dopamine agonists on neuropsychiatric symptoms of Parkinson’s disease. Neurodegener Dis 7(1–3):206–209. 10.1159/000295665 PubMed

MacDonald PA, MacDonald AA, Seergobin KN et al (2011) The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson’s disease: support from functional MRI. Brain 134(Pt 5):1447–1463. 10.1093/brain/awr075 PubMed

Torta DME, Castelli L, Zibetti M, Lopiano L, Geminiani G (2009) On the role of dopamine replacement therapy in decision-making, working memory, and reward in Parkinson’s disease: does the therapy-dose matter? Brain Cogn 71(2):84–91. 10.1016/j.bandc.2009.04.003 PubMed

Friederici AD (2018) The neural basis for human syntax: Broca’s area and beyond. Curr Opin Behav Sci 21:88–92. 10.1016/j.cobeha.2018.03.004

Teichmann M, Gaura V, Démonet JF et al (2008) Language processing within the striatum: evidence from a PET correlation study in Huntington’s disease. Brain 131(Pt 4):1046–1056. 10.1093/brain/awn036 PubMed

Jacquemot C, Bachoud-Lévi AC (2021) Striatum and language processing: where do we stand? Cognition 213:104785. 10.1016/j.cognition.2021.104785 PubMed

Arantes PR, Gobato HH, Davoglio BB et al (2012) Levodopa versus non-levodopa brain language fMRI in Parkinson’s disease. Einstein (Sao Paulo) 10(2):171–179. 10.1590/s1679-45082012000200010 PubMed

Moro A, Tettamanti M, Perani D, Donati C, Cappa SF, Fazio F (2001) Syntax and the brain: disentangling grammar by selective anomalies. Neuroimage 13(1):110–118. 10.1006/nimg.2000.0668 PubMed

Teichmann M, Rosso C, Martini JB et al (2015) A cortical-subcortical syntax pathway linking Broca’s area and the striatum. Hum Brain Mapp 36(6):2270–2283. 10.1002/hbm.22769 PubMed PMC

Rusz J, Tykalova T, Novotny M et al (2021) Defining speech subtypes in de novo parkinson disease: response to long-term levodopa therapy. Neurology 97(21):e2124–e2135. 10.1212/WNL.0000000000012878 PubMed

Subert M, Tykalova T, Novotny M, Bezdicek O, Dusek P, Rusz J (2025) Automated analysis of spoken language differentiates multiple system atrophy from Parkinson’s disease. J Neurol Published online. 10.1007/s00415-024-12828-w PubMed PMC

Gorno-Tempini ML, Hillis AE, Weintraub S et al (2011) Classification of primary progressive aphasia and its variants. Neurology 76(11):1006–1014. 10.1212/WNL.0b013e31821103e6 PubMed PMC

Gordon JK, Young M, Garcia C (2018) Why do older adults have difficulty with semantic fluency? Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 25(6):803–828. 10.1080/13825585.2017.1374328 PubMed

Illner V, Novotný M, Kouba T et al (2024) Smartphone voice calls provide early biomarkers of parkinsonism in rapid eye movement sleep behavior disorder. Mov Disord 39(10):1752–1762. 10.1002/mds.29921 PubMed

Cooley SA, Heaps JM, Bolzenius JD et al (2015) Longitudinal change in performance on the montreal cognitive assessment in older adults. Clin Neuropsychol 29(6):824–835. 10.1080/13854046.2015.1087596 PubMed PMC